IONS
NASDAQIonis Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News · 26 weeks100-93%
2026-03-012026-08-23
Mix5290d
- Insider27(52%)
- Other12(23%)
- SEC Filings9(17%)
- Analyst2(4%)
- Leadership1(2%)
- Earnings1(2%)
Latest news
25 items- PRIonis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that new data in the management of severe hypertriglyceridemia (sHTG) will be presented at the European Society of Cardiology (ESC) Congress 2026, taking place August 28 – 31 in Munich. Presentations include one-year data from the open-label, long-term extension study of TRYNGOLZA® (olezarsen), recently approved in the U.S. as the first and only treatment for sHTG to reduce triglycerides and the risk of acute pancreatitis, and Phase 1 data in hypertriglyceridemia for ION775, an investigational siRNA and next-generation follow-on to TRYNGOLZA with the potential for semiannual or less frequent dosing. "People living with sHTG face th
- ANALYSTBMO Capital Markets initiated coverage on Ionis Pharma with a new price targetBMO Capital Markets initiated coverage of Ionis Pharma with a rating of Market Perform and set a new price target of $60.00
- INSIDERDirector Hayden Michael R bought $1,058,700 worth of shares (20,000 units at $52.94) (SEC Form 4)4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- SECSEC Form S-8 filed by Ionis Pharmaceuticals Inc.S-8 - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
- SECSEC Form 10-Q filed by Ionis Pharmaceuticals Inc.10-Q - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
- SECIonis Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
- PRIonis announces Dr. Frank Bennett, chief scientific officer, to retireIonis Pharmaceuticals, Inc. (NASDAQ:IONS) announced today that Frank Bennett, Ph.D., executive vice president and chief scientific officer, will retire effective February 2027."As a founding scientist, Frank has been instrumental in shaping Ionis and advancing the entire field of RNA-targeted medicines," said Brett P. Monia, Ph.D., chief executive officer, Ionis. "Frank’s profound contributions include pioneering the use of antisense medicines in neurological disease. He led the discovery and development of the first approved medicines for spinal muscular atrophy and a genetic form of amyotrophic lateral sclerosis, which have transformed the lives of thousands of people. We are deeply gratef
- PRIonis reports second quarter 2026 financial results and highlights progress on key programs- TRYNGOLZA® (olezarsen) demonstrating early sHTG launch momentum, underscoring multi-billion-dollar revenue potential in large patient population – - Completed enrollment in Phase 3 REVEAL trial in Angelman syndrome - - On track to achieve 2026 financial guidance - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company") today reported financial results and provided key updates for the second quarter ended June 30, 2026. "With the approval of TRYNGOLZA in late June, Ionis is bringing the first and only treatment to reduce triglycerides and acute pancreatitis to people living with severe hypertriglyceridemia. We are encouraged by the early launch momentum and look forward to accele
- INSIDERSEC Form 4 filed by Director Reikes Peter N4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDERSEC Form 4 filed by Director Hantson Ludwig4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDERDirector Herman Joan E converted options into 5,220 shares, increasing direct ownership by 11% to 51,306 units (SEC Form 4)4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDERDirector Berthelsen Spencer R converted options into 5,220 shares, increasing direct ownership by 3% to 161,233 units (SEC Form 4)4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- ANALYSTIonis Pharma downgraded by Wolfe ResearchWolfe Research downgraded Ionis Pharma from Outperform to Peer Perform
- PRIonis to hold second quarter 2026 financial results webcastWebcast scheduled for Wednesday, July 29 at 8:30 a.m. Eastern TimeIonis Pharmaceuticals, Inc. (NASDAQ:IONS) announced today that it will host a live webcast on Wednesday, July 29 at 8:30 a.m. Eastern Time to discuss its second quarter 2026 financial results and highlight progress on key programs.The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address.About Ionis Pharmaceuticals, Inc.For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has marketed medicines and a leading pipeline in neurology, cardiometabolic disease and
- PRIonis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease- Clinical outcomes: Diranersen demonstrated efficacy across all studied doses at 18 months, with consistent results across multiple prespecified clinical endpoints; the 60 mg dose showed the strongest response with slowing of clinical decline on the cognitive endpoints—42% on ADAS-Cog13 and 50% on MMSE—alongside a 26% slowing on CDR-SB - - Biomarker response: Diranersen is the first tau-directed therapy to demonstrate robust reductions in both CSF total tau, with mean reductions of 50–65%, and brain tau pathology, as measured by PET, across all studied doses in a Phase 2 study - - Dose response: CDR-SB results favored diranersen versus placebo across all studied doses; higher doses wer
- PRIonis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndromeIonis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that the first participant has been dosed in the Phase 1-2 ASCEND study of ION337, an investigational RNA-targeted medicine for people living with Dravet syndrome, a rare, severe and lifelong neurological disorder. Dravet syndrome typically begins in infancy and is associated with prolonged seizures, developmental delays, cognitive impairments and an increased risk of sudden death. "The first participant to receive ION337 in the ASCEND study marks an important step toward advancing a potential disease modifying therapy for people living with Dravet syndrome," said Holly Kordasiewicz, Ph.D., executive vice president, chief developme
- SECIonis Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
- INSIDEREVP, Chief Scientific Officer Bennett C Frank sold $1,744,623 worth of shares (20,536 units at $84.95) as part of a pre-agreed trading plan and acquired 15,000 shares as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 75,018 units (SEC Form 4)4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDERDirector Diaz Allene M. sold $863,637 worth of shares (10,111 units at $85.42) as part of a pre-agreed trading plan and exercised 10,111 shares at a strike of $47.11 (SEC Form 4)4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDEREVP, Chief Development Officer Kordasiewicz Holly B. sold $30,517 worth of shares (362 units at $84.30) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 22,096 units (SEC Form 4)4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- SECIonis Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
- PRUpdate on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy– Study missed primary endpoint of composite outcome of cardiovascular (CV) mortality and recurrent CV events; in a pre-specified subgroup analysis, a nominally significant result was observed with eplontersen monotherapy – – Favorable safety profile consistent with previous results – Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) and partner AstraZeneca today announced that the CARDIO-TTRansform Phase 3 trial for eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary efficacy endpoint of the composite outcome of cardiovascular (CV) mortality and recurrent CV clinical events up to Week 140 compared with placebo. In this contemporary pati
- INSIDERSEC Form 4 filed by Director Yang Michael J.4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDERSEC Form 4 filed by Director Loscalzo Joseph4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDERSEC Form 4 filed by Director Herman Joan E4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
IONS FAQ
6 questionsWhat does Ionis Pharmaceuticals Inc. do?
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases...Where does IONS stock trade?
Ionis Pharmaceuticals Inc. (IONS) is listed on NASDAQ.What sector and industry is IONS in?
Ionis Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about IONS?
Ionis Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from BMO Capital Markets: Market Perform on 2026-08-19.What companies are similar to IONS?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare IONS side-by-side with any of them on Quantisnow.How can I track IONS on Quantisnow?
Quantisnow aggregates Ionis Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IONS to receive live email and push alerts on every new disclosure.